A phase II dose-ranging study of mirabegron in patients with overactive bladder

被引：0
|
作者：
Christopher R. Chapple
Vladimir Dvorak
Pjotr Radziszewski
Philip Van Kerrebroeck
Jean Jacques Wyndaele
Brigitte Bosman
Peter Boerrigter
Ted Drogendijk
Arwin Ridder
Ingrid Van Der Putten-Slob
Osamu Yamaguchi
机构：
[1] Sheffield Teaching Hospitals,Department of Urology, Royal Hallamshire Hospital
[2] Centrum ambulantní gynekologie a primární péce,Department of Urology
[3] Medical University Warsaw,Department Urology
[4] Maastricht University Medical Center,Department of Urology
[5] Antwerp University and Antwerp University Hospital,Division of Bioengineering and LUTD Research, School of Engineering
[6] Astellas Pharma Europe BV,undefined
[7] Nihon University,undefined
来源：
International Urogynecology Journal | 2013年 / 24卷
关键词：
β; -adrenoceptor agonist; Mirabegron; Overactive; Urinary bladder;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1447 / 1458
页数：11
相关论文
共 50 条
  • [21] Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study)
    Hiroshi Nakagomi
    Takahiko Mitsui
    Hiroshi Shimura
    Tatsuya Ihara
    Satoru Kira
    Norifumi Sawada
    Masayuki Takeda
    BMC Urology, 22
  • [22] Combined treatment of solifenacin and mirabegron, an alternative in patients with overactive bladder (BESIDE study)
    Alcantara-Montero, A.
    ACTAS UROLOGICAS ESPANOLAS, 2016, 40 (09): : 593 - 594
  • [23] Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study)
    Nakagomi, Hiroshi
    Mitsui, Takahiko
    Shimura, Hiroshi
    Ihara, Tatsuya
    Kira, Satoru
    Sawada, Norifumi
    Takeda, Masayuki
    BMC UROLOGY, 2022, 22 (01)
  • [24] Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder
    Christopher R. Chapple
    Victor W. Nitti
    Vik Khullar
    Jean Jacques Wyndaele
    Sender Herschorn
    Philip van Kerrebroeck
    Mary Beth Blauwet
    Emad Siddiqui
    World Journal of Urology, 2014, 32 : 1565 - 1572
  • [25] Sensitivity to zidovudine and saquinavir in the phase I/II dose-ranging saquinavir trial
    Collin, G
    Dussaix, E
    Krivine, A
    Letourneur, F
    Descamps, D
    Delfraissy, JF
    BrunVezinet, F
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1995, 10 : 49 - 49
  • [26] Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder
    Chapple, Christopher R.
    Nitti, Victor W.
    Khullar, Vik
    Wyndaele, Jean Jacques
    Herschorn, Sender
    van Kerrebroeck, Philip
    Blauwet, Mary Beth
    Siddiqui, Emad
    WORLD JOURNAL OF UROLOGY, 2014, 32 (06) : 1565 - 1572
  • [27] Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study
    Hanotin, C
    Thomas, F
    Jones, SP
    Leutenegger, E
    Drouin, P
    INTERNATIONAL JOURNAL OF OBESITY, 1998, 22 (01) : 32 - 38
  • [28] A Dose-Ranging Study of Diacerein in Patients With Type 2 Diabetes
    Brown, Carl O.
    Lu, Weishu
    Lin, Emily
    Chen, Calvin
    DIABETES, 2013, 62 : A272 - A273
  • [29] Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study
    C Hanotin
    F Thomas
    SP Jones
    E Leutenegger
    P Drouin
    International Journal of Obesity, 1998, 22 : 32 - 38
  • [30] A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group)
    M. Shiraki
    M. Fukunaga
    K. Kushida
    H. Kishimoto
    Y. Taketani
    H. Minaguchi
    T. Inoue
    R. Morita
    H. Morii
    K. Yamamoto
    Y. Ohashi
    H. Orimo
    Osteoporosis International, 2003, 14 : 225 - 234
12345